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 29 
Abstract 30 
BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours 31 
hypersensitive to PARP inhibitors. To understand resistance mechanisms, we conducted 32 
whole-genome CRISPR-Cas9 synthetic-viability/resistance screens in BRCA1-deficient 33 
breast cancer cells treated with PARP inhibitors. We identified two previously 34 
uncharacterized proteins, C20orf196 and FAM35A, whose inactivation confers strong PARP-35 
inhibitor resistance. Mechanistically, we show C20orf196 and FAM35A form a complex, 36 
ÒShieldinÓ (SHLD1/2), with FAM35A interacting with single-stranded DNA via its C-37 
terminal OB fold region. We establish that Shieldin acts as the downstream effector of 38 
53BP1/RIF1/MAD2L2 to promote DNA double-strand break (DSB) end-joining through 39 
restricting DSB resection and counteract homologous recombination by antagonising 40 
BRCA2/RAD51 loading in BRCA1-deficient cells. Notably, Shieldin inactivation further 41 
sensitises BRCA1-deficient cells to cisplatin, suggesting how defining the SHLD1/2 status of 42 
BRCA1-deficient tumours might aid patient stratification and yield new treatment 43 
opportunities. Highlighting this potential, we document reduced SHLD1/2 expression in 44 
human breast cancers displaying intrinsic or acquired PARP-inhibitor resistance. 45 
 46 
Introduction 47 
DNA double-strand breaks (DSBs) are highly cytotoxic cellular lesions that must be 48 
effectively and accurately repaired to maintain genome stability and prevent premature aging, 49 
neurodegeneration, immunodeficiency, cancer and other diseases
1-3
. In response to DSB 50 
detection, the apical kinases ATM, ATR and PRKDC (DNA-PKcs) become activated and 51 
phosphorylate numerous substrates to initiate the cellular DNA damage response (DDR)
4
. 52 
The ensuing cascade of molecular DDR events, which are promoted by various post-53 
translational modifications including protein phosphorylation, ubiquitylation, sumoylation 54 
and poly (ADP-ribosyl)ation, impacts on a myriad of cellular components, amongst other 55 
things leading to assembly of DDR factors at DNA-damage sites, arrest or slowing of cell-56 
cycle progression, and activation of DNA repair mechanisms
4, 5
.  The two main types of 57 
DSB-repair pathway are non-homologous end-joining (NHEJ) which is active throughout the 58 
cell cycle, and homologous recombination (HR), which normally requires a sister chromatid 59 
as a template and hence only operates in S and G2 phases of the cell cycle. DSB-repair 60 
pathway choice is partly determined by functional antagonism between the HR-promoting 61 
factor BRCA1 and NHEJ-promoting proteins such as TP53BP1 (53BP1), RIF1 and MAD2L2 62 
(REV7)
6-13
. 63 
 64 
Inherited or acquired mutations in the BRCA1 or BRCA2 genes that result in protein loss or a 65 
mutant BRCA1/2 protein cause breast, ovarian, prostate and other cancers, and render 66 
tumours hypersensitive to PARP-inhibitor drugs such as olaparib
14-17
. Unfortunately, intrinsic 67 
or acquired PARP-inhibitor resistance frequently leads to lack-of-response or to patient 68 
relapse and tumour regrowth
15, 18
. In the clinic, the most common PARP-inhibitor resistance 69 
mechanisms reported to date are restoration of BRCA1/2 expression or function. Notably, 70 
53BP1 expression is lost in various triple-negative breast cancers
7
, which may account for 71 
certain clinically relevant examples of PARP-inhibitor resistance. Nevertheless, the 72 
mechanisms driving PARP-inhibitor resistance in a large proportion of BRCA1/2-deficient 73 
tumours remain unexplained
18, 19
. 74 
 75 
To systematically survey for genetic mechanisms of PARP-inhibitor resistance, we conducted 76 
whole-genome CRISPR-Cas9 synthetic-viability/resistance screens in human BRCA1-77 
deficient breast cancer cells treated with PARP inhibitors. In addition to identifying known 78 
resistance factors such as 53BP1, RIF1 and MAD2L2 loss
6-13
, we identified two previously 79 
uncharacterized proteins, C20orf196 and FAM35A, whose inactivation confers PARP-80 
inhibitor resistance to BRCA1-deficient cells. Our ensuing work lead us to define the 81 
ÒShieldinÓ (SHLD1
C20orf196
/SHLD2
FAM35A
) complex that promotes NHEJ by serving as the 82 
downstream effector of 53BP1, RIF1 and MAD2L2, restricts DSB resection, and counteracts 83 
HR in BRCA1-deficient cells by antagonising replacement of replication protein A (RPA) 84 
with BRCA2 and RAD51 on resected single-stranded DNA (ssDNA). Finally, we report that 85 
SHLD1
C20orf196
/SHLD2
FAM35A
 loss confers hypersensitivity to the DNA-crosslinking agent 86 
cisplatin, and that reduced SHLD1
C20orf196
 or SHLD2
FAM35A
 expression is associated with 87 
evolution of PARP-inhibitor resistance in a patient-derived BRCA1-deficient breast cancer 88 
xenograft model and in BRCA1-mutant cancers displaying intrinsic PARP-inhibitor 89 
resistance. 90 
 91 
Results 92 
FAM35A or C20orf196 loss suppresses PARP-inhibitor sensitivity of BRCA1-mutant 93 
cells 94 
To systematically explore genetic mechanisms imparting PARP-inhibitor resistance, we 95 
carried out genome-wide CRISPR-Cas9 gene-inactivation screens with the GeCKO library
20
 96 
in the BRCA1-mutant breast cancer cell line SUM149PT treated in parallel with the PARP 97 
inhibitors olaparib, talazoparib (BMN673) or AZD2461 (Fig 1a, b, Supplementary Fig 1a-c). 98 
In addition to identifying the known resistance genes TP53BP1, RIF1 and MAD2L2 whose 99 
products form a complex
21
, we identified several new suppressor candidates (Supplementary 100 
Table 1, Supplementary Fig 1d-e). These included DYNLL1, a known 53BP1 interaction 101 
partner
22
, and TEN1, a component of the CST telomere-capping complex 102 
(CTC1/STN1/TEN1) that also promotes telomere DNA replication
23
. In our ensuing studies, 103 
however, we focused on the uncharacterised proteins FAM35A and C20orf196 that 104 
collectively received the highest scores from our screens (Fig 1b and Supplementary Table 105 
1). Thus, by carrying out short-interfering RNA (siRNA) mediated mRNA silencing in non-106 
transformed, hTERT immortalized human RPE1 cells (Supplementary Fig 1f), we established 107 
that, as for 53BP1 loss
7
, depletion of FAM35A or C20orf196 markedly suppressed PARP-108 
inhibitor sensitivity caused by BRCA1 inactivation while having no discernible effect in 109 
BRCA1-proficient cells (Fig 1c, Supplementary Fig 1g). This conclusion was independently 110 
confirmed by de novo CRISPR-Cas9 gene editing, with FAM35A or C20orf196 inactivation 111 
alleviating the olaparib hypersensitivity of BRCA1-deficient cells in a manner counteracted 112 
by re-introduction of wild-type FAM35A or C20orf196 (Fig 1d-e; Supplementary Fig 1h; as 113 
shown in supplementary Fig 1i, these effects did not reflect altered cell-cycle profiles).  114 
 115 
The FAM35A/C20orf196 complex interacts with and acts downstream of 116 
53BP1/RIF1/MAD2L2  117 
Sequence analyses indicated that FAM35A and C20orf196 are well conserved in vertebrates. 118 
Moreover, structure prediction modelling (RaptorX; http://raptorx.uchicago.edu/) revealed 119 
that FAM35A harbours a disordered N-terminus and an ordered C-terminal region containing 120 
three OB folds, with the last C-terminal OB fold/FAM domain containing a CXXC-type zinc 121 
finger motif (Fig 2a). Notably, this organization is highly similar to those of the RPA1 122 
subunit of ssDNA binding protein RPA and the CTC1 subunit of the CST complex that also 123 
binds ssDNA
23
. In this regard, we noted that while the C20orf196 N-terminus (residues 1-70) 124 
is predicted to be intrinsically disordered, its C-terminal part is more structured and may 125 
harbour one- or two-winged helix (WH) domains (Fig 2a) similar to those in the yeast CST 126 
subunit Stn1
23, 24
, suggesting that C20orf196 and Stn1 might play analogous or 127 
complementary roles.  128 
 129 
Through combining cellular co-localization and co-immunoprecipitation experiments, we 130 
established that FAM35A and C20orf196 directly interact in a manner that is mainly, but not 131 
exclusively, mediated by the FAM35A OB3/FAM domain (Fig 2b-c, Supplementary Fig 2a-132 
b). Because loss of FAM35A or C20orf196 had similar effects to loss of 133 
53BP1/RIF1/MAD2L2 in BRCA1-deficient cells, we tested for possible interactions between 134 
these factors. Thus, via co-immunoprecipitation and mass spectrometry (MS) studies, we 135 
found that both C20orf196 and FAM35A interact with MAD2L2, the most distal factor of the 136 
53BP1/RIF1/MAD2L2 axis mediating PARP-inhibitor sensitivity in BRCA1-deficient cells
6-
137 
13
 (Fig 2d, Supplementary Fig 2c).  138 
 139 
Many DDR proteins accumulate at DSB sites within ionizing radiation (IR)-induced nuclear 140 
foci (IRIF)
5
. We established that both FAM35A and C20orf196 formed IRIF, and by live-cell 141 
imaging studies found that the proteins were also recruited to localised DNA-damage sites 142 
induced by laser micro-irradiation (Supplementary Fig 2d). Furthermore, we determined by 143 
confocal and super-resolution microscopy that FAM35A co-localised with the established 144 
DSB markers phosphorylated histone H2AFX
25
 (gH2AX) and 53BP1
26
 (Fig 2e-f, 145 
Supplementary Fig 2e). Notably, siRNA/shRNA-depletion experiments established that while 146 
53BP1 IRIF and MAD2L2 levels and IRIF were not significantly impaired by FAM35A or 147 
C20orf196 depletion (Supplementary Fig 2f-h), IRIF formation by FAM35A and C20orf196 148 
required 53BP1, RIF1 and MAD2L2 but not PTIP (Fig 2e and Supplementary Fig 3a-c; note 149 
that total levels of GFP-tagged FAM35A/C20orf196 were minimally affected by 150 
53BP1/RIF1/MAD2L2 depletion). We also established that C20orf196 IRIF were almost 151 
totally abrogated by FAM35A depletion, while C20orf196 depletion reduced but did not 152 
abolish FAM35A IRIF (Fig 2e). In addition, FAM35A formed nuclear foci when cells were 153 
treated with the DNA topoisomerase I inhibitor camptothecin (CPT; Supplementary Fig 3d). 154 
Significantly, the FAM35A N-terminus was necessary and sufficient for its IRIF formation, 155 
these IRIF depended on 53BP1, RIF1, MAD2L2 and C20orf196, and this region could be co-156 
immunoprecipitated with MAD2L2 (Fig 2f-g, Supplementary Fig 3e-f). Collectively, these 157 
findings indicated that FAM35A and C20orf196 act as downstream components of the 158 
53BP1/RIF1/MAD2L2 molecular assembly
21
 at DSB sites.  159 
 160 
FAM35A and C20orf196 promote NHEJ 161 
Since 53BP1, RIF1 and MAD2L2 promote NHEJ
6-13
, we tested whether FAM35A and 162 
C20orf196 fulfil a similar role. Indeed, as for depletion of the NHEJ factor XRCC4, siRNA 163 
depletion of 53BP1, FAM35A or C20orf196 impaired NHEJ as measured by random 164 
integration of plasmid DNA into chromosomes
27
 (Fig 3a). In addition, FAM35A or 165 
C20orf196 depletion conferred IR hypersensitivity to both human and mouse cells (Fig 3b 166 
and Supplementary Fig 4a). 53BP1 and associated factors promote NHEJ-mediated class-167 
switch recombination (CSR) at the immunoglobulin heavy-chain locus, a process that allows 168 
B-lymphocytes to change antibody production from one type to another
28
.  By CRISPR-Cas9 169 
gene editing in mouse CH12F3 (CH12) B-lymphocytes
29
 we established that, as for 170 
53BP1/RIF1/MAD2L2 inactivation
6, 8, 10-12, 30, 31
, loss of FAM35A or C20orf196 markedly 171 
reduced CSR (Fig 3c-d and Supplementary Fig 4b-d). Furthermore, analysis of metaphase 172 
chromosomal spreads of such cells revealed that FAM35A or C20orf196 inactivation led to 173 
chromosomal breaks and translocations symptomatic of aberrant CSR
32
 (Fig 3e-f;  note from 174 
Supplementary Fig 4e-f that CSR effects were not associated with defects in cell 175 
proliferation, or in Aid or germ-line Sa switch region transcription). 176 
 177 
FAM35A and C20orf196 antagonise DNA-end resection  178 
To explore FAM35A and C20orf196 function further, we carried out assays in mouse cells 179 
harbouring a temperature-sensitive allele of the telomere-associated factor TRF2 (TRF2ts). 180 
TRF2ts inactivation at higher temperatures results in de-protected chromosome ends and 181 
causes NHEJ-mediated telomere fusions (Fig 4a)
6, 33
. Strikingly, through use of short-hairpin 182 
RNA (shRNA) mediated mRNA silencing, we found that such chromosome fusions were 183 
diminished by FAM35A or C20orf196 depletion like that elicited by MAD2L2 depletion (Fig 184 
4b, Supplementary Fig 5a-b). 	185 
 186 
The impacts of 53BP1, RIF1 or MAD2L2 depletion in the TRF2ts system are connected to 187 
these factors counteracting DSB resection
6-13, 34
. We thus explored whether FAM35A and 188 
C20orf196 might also have this function. Indeed, as for 53BP1/RIF1/MAD2L2 inactivation
6-
189 
13, 35
, loss of FAM35A or C20orf196 in human cells enhanced DSB-resection as measured by 190 
RPA and ssDNA staining intensity in pre-extracted nuclei after treatment with camptothecin 191 
(Fig 4c-e; RPA1 kinetics at DNA damage sites induced by laser micro-irradiation were not 192 
altered by FAM35A or C20orf196 depletion, Supplementary Fig 5c). In line with this 193 
resection being mediated by canonical pathways, it was diminished by depletion of the 194 
resection promoting factors RBBP8 (CtIP) or BLM (Fig 4f). Furthermore, we established that 195 
recruitment of BLM to sites of laser micro-irradiation was enhanced by FAM35A or 196 
C20orf196 depletion (Fig 4g). Similarly, as shown for 53BP1 depletion in mouse cells
6
, 197 
FAM35A or C20orf196 depletion in such cells led to higher levels of the DNA-end resection 198 
marker, Ser4/8 phosphorylated RPA2, after IR treatment (Fig 4d). Together with our other 199 
findings, these data established FAM35A and C20orf196 as crucial components of 200 
53BP1/RIF1/MAD2L2-mediated chromosomal NHEJ, and suggested that their pro-NHEJ 201 
function is connected to limiting DSB resection. 202 
 203 
The FAM35A OB fold region interacts with ssDNA and promotes IR survival 204 
Consistent with our prediction of structural similarity between FAM35A and RPA1, the 205 
FAM35A C-terminus could be retrieved from cell extracts via interaction with a ssDNA 206 
oligonucleotide (Fig 5a). Sequence alignment to RPA1 and structural modelling of FAM35A 207 
identified two Trp (W) residues predicted to be at the protein-ssDNA interface, based on 208 
analogous residues critical for RPA binding to ssDNA (Fig 5b, Supplementary Fig 5d). In 209 
accord with this prediction, we found via electrophoretic gel-mobility shift assays (EMSAs) 210 
that the bacterially-expressed, purified FAM35A C-terminal region bound preferentially to 211 
ssDNA rather than double-stranded DNA (Fig 5c, Supplementary Fig 5e), and ssDNA 212 
binding was reduced when the two Trp residues were mutated to Ala (W489/W640A; Fig 213 
5c). Furthermore, while full-length FAM35A bearing these mutations (FAM35A
W489/W640A
) 214 
still interacted with C20orf196 (Supplementary Fig 5f) and formed IRIF in cells, these IRIF 215 
were consistently less pronounced than those of the wild-type FAM35A protein (Fig 5d). 216 
This suggested that following IRIF recruitment via its N-terminal region, the FAM35A C-217 
terminal ssDNA binding region may allow further FAM35A recruitment, retention and/or 218 
stabilization. In addition, unlike the wild-type protein, FAM35A
W489/W640A
 did not confer 219 
significant IR resistance when reintroduced into FAM35A null cells (Fig 5e). In parallel 220 
studies, expression of the FAM35A C-terminus did not complement the IR hypersensitivity 221 
of FAM35A
 
null cells. Moreover, expression of the FAM35A N-terminus rendered cells IR 222 
hypersensitive irrespective of whether they expressed endogenous FAM35A, implying that 223 
the N-terminal IRIF-forming domain of FAM35A may have a dominant-negative effect on 224 
NHEJ (Fig 5f; overexpression of these FAM35A derivatives did not affect olaparib 225 
sensitivity in a wild-type background, Supplementary Fig 5g).  226 
 227 
FAM35A and C20orf196 antagonise HR in BRCA1-deficient cells 228 
PARP inhibitors generate replication-associated DNA lesions that require BRCA1-mediated 229 
HR for their effective repair
19
, and loss of 53BP1/RIF1/MAD2L2 partly restores the ability of 230 
BRCA1-deficient cells to repair such lesions
6-13
. This has led to a model in which BRCA1 231 
and 53BP1/RIF1/MAD2L2 play antagonistic roles in channelling DSBs towards HR or 232 
NHEJ, respectively. We thus speculated that BRCA1 might antagonise FAM35A/C20orf196 233 
action. Accordingly, both FAM35A and C20orf196 IRIF, but not 53BP1 IRIF, were 234 
significantly enhanced in number and intensity upon BRCA1 but not BRCA2 depletion (Fig 235 
6a-b, Supplementary Fig 6a-b). 236 
 237 
Collectively, our results suggested that FAM35A/C20orf196 act at the interface between the 238 
opposing functions of BRCA1 and 53BP1/RIF1/MAD2L2 to regulate DSB-repair pathway 239 
choice. While this action could operate at least in part through control of DSB resection, 240 
which is misregulated and of slower kinetics in BRCA1-deficient cells
11, 36
, we reasoned that 241 
FAM35A/C20orf196 might also contribute to the severe defect in BRCA2-mediated RAD51 242 
loading at DNA-damage sites in BRCA1-deficient cells
11, 35, 37
. Indeed, as for 53BP1 243 
inactivation, loss of FAM35A or C20orf196 restored RAD51 IRIF formation in BRCA1-null 244 
cells (Fig 6c). While exploring the mechanism for this effect, we found elevated resection 245 
levels in FAM35A and C20orf196 knockout cells, as measured by RPA recruitment at DNA-246 
damage sites, were still maintained in the absence of BRCA1 (Supplementary Fig 6c-d). 247 
Furthermore, FAM35A/C20orf196 depletion also alleviated the impaired recruitment of 248 
BRCA2 to DNA-damage sites in BRCA1-deficient cells (Fig 6d, Supplementary Fig 6e). 249 
Accordingly, studies with a cell-based chromosomal traffic light reporter (TLR) HR system 250 
38, 39
 established that FAM35A or C20orf196 depletion in BRCA1-deficient cells restored HR 251 
to levels similar to those acquired upon 53BP1 depletion in this setting (Fig 6e, 252 
Supplementary 6f). In addition, removing FAM35A or C20orf196 rescued the spontaneous 253 
genomic instability phenotype of BRCA1 knockout cells (Fig 6f). Building on our findings 254 
that the FAM35A N-terminal region largely mediates its localisation to IRIF (Fig 2f, 255 
Supplementary Fig 3e-f), introducing the FAM35A N-terminus, but not the C-terminus, 256 
enhanced PARP-inhibitor sensitivity of BRCA1/FAM35A null cells (Fig 6g, Supplementary 257 
Fig 6g). Furthermore, FAM35A inactivation was epistatic to 53BP1 inactivation in relation to 258 
conferring PARP-inhibitor resistance in BRCA1 knockout cells (Supplementary Fig 6h). 259 
Considering our findings together, we propose that C20orf196 and FAM35A be named 260 
SHLD1 and SHLD2, respectively, or collectively as the ÒShieldin complexÓ because it 261 
shields DSBs from inappropriate activities and promotes appropriate modes of DSB repair. 262 
 263 
FAM35A/C20orf196 loss correlates with PARP inhibitor resistance in cancers 264 
Having identified SHLD1
C20orf196
 and SHLD2
FAM35A
 as mediating the PARP-inhibitor 265 
sensitivity of a BRCA1-deficient breast cancer cell line, we speculated that this might also 266 
apply in more physiological settings. Consequently, we employed a patient-derived xenograft 267 
(PDX) model of BRCA1-deficient breast cancer propagated in mice in the presence (cohort 268 
2) or absence (cohort 1) of olaparib (Fig 7a). The resistant tumour was further serially 269 
passaged into new hosts that were treated in the presence (cohort 4) or absence (cohort 3) of 270 
olaparib to confirm and sustain drug resistance (Fig 7a; see also Supplementary Fig 7a). The 271 
tumours were then harvested and subjected to whole-genome RNA-sequencing. Notably, our 272 
analyses revealed that in contrast to the other cohorts, nearly all resistant tumours after 273 
chronic olaparib treatment (cohort 4) correlated with reduced mRNA expression of 274 
SHLD1
C20orf196
, SHLD2
FAM35A
, 53BP1 and/or PARP1 (Fig 7a; each heatmap column 275 
represents one tumour/mouse sample). Because this tumour model is polyclonal
40
, our data 276 
suggested that olaparib resistance mechanisms might arise through parallel evolutionary 277 
trajectories converging on loss of Shieldin activity. Furthermore, when we stratified a cohort 278 
of BRCA1-deficient PDX tumours by SHLD1/2 expression, ensuing analyses indicated that 279 
low SHLD1
C20orf196 
transcript levels correlated with intrinsic olaparib resistance (Fig 7b). One 280 
of the olaparib resistant models (PDX127) demonstrated concomitant loss of both 281 
SHLD1
C20orf196
 and SHLD2
FAM35A
, while two other resistant models exhibiting normal 282 
SHLD1/2 transcript levels harboured deleterious 53BP1 mutations. Notably, several of these 283 
resistant PDX models also display BRCA1 nuclear foci
41
, suggesting the presence of multiple 284 
mechanisms of resistance, due to tumour heterogeneity and/or mechanistic cooperation. 285 
 286 
Finally, we found that in contrast to 53BP1 deficiency
42
, SHLD1
C20orf196
 or SHLD2
FAM35A
 287 
loss increased the sensitivity of BRCA1-proficient and BRCA1-null cells to IR, and even 288 
more markedly enhanced their sensitivity to the DNA crosslinking agent cisplatin (Fig 7c-d, 289 
Supplementary Fig 7b-c). Furthermore, enhanced cisplatin sensitivity upon SHLD1
C20orf196
 or 290 
SHLD2
FAM35A 
inactivation was associated with increased DNA-damage focus formation by 291 
the FANCD2 protein that is involved in detection and repair of DNA crosslinks (Fig 7e, 292 
Supplementary Fig 7d). These findings therefore suggested that, if loss/reduced expression of 293 
SHLD1/2 occurs in patients, it may provide collateral therapeutic vulnerabilities that could be 294 
exploited clinically. 295 
 296 
Discussion 297 
Over the past two decades, it has become evident that eukaryotic cells have evolved multiple 298 
mechanisms of DNA DSB repair that are regulated in complex and sophisticated ways to 299 
optimise genome stability. In particular, much attention has focused on how cells 300 
strategically employ the two prime modes of DSB repair Ð NHEJ and HR Ð which antagonise 301 
one another, operate optimally in different contexts and whose relative usage is regulated by 302 
factors such as chromatin structure and cell-cycle stage. In addition to being of academic 303 
interest, work on such subjects is also of clinical relevance, particularly in cancer therapy 304 
where DSB-inducing chemotherapeutic agents are frequently used, and molecularly-targeted 305 
drugs such as PARP inhibitors are being increasingly employed in specific settings. Intrinsic 306 
or arising PARP-inhibitor resistance in patients with BRCA1/2 mutations is nevertheless an 307 
increasing clinical problem. Using whole-genome CRISPR-Cas9 synthetic-308 
viability/resistance screens, we have uncovered two, previously uncharacterised proteins Ð 309 
SHLD1
C20orf196
 and SHLD2
FAM35A
 Ð whose loss mediates PARP-inhibitor resistance and 310 
which we have shown act as the most distal factors of the 53BP1/RIF1/MAD2L2 molecular 311 
axis to promote NHEJ and restrict HR in BRCA1-deficient settings. Our screens have also 312 
identified additional candidate PARP-inhibitor resistance factors that await validation in 313 
future studies.  314 
 315 
Mechanistically, we have shown that SHLD1
C20orf196
 and SHLD2
FAM35A
 form a complex, 316 
termed Shieldin, with SHLD1
C20orf196 
recruitment to DNA-damage sites via its interactions 317 
with SHLD2
FAM35A
 and other factors, and SHLD2
FAM35A
 interacting with single-stranded 318 
DNA via its C-terminal OB fold region. Moreover, we have established that SHLD1
C20orf196
 319 
and SHLD2
FAM35A
 promote NHEJ in a manner that may be mediated via their effects on 320 
restricting DNA-end resection, and serve as a barrier to HR by antagonising the replacement 321 
of RPA with BRCA2/RAD51 on resected ssDNA in a manner counteracted by BRCA1. Our 322 
work is in line with a recent report
43
, that independently identified SHLD1
C20orf196
 and 323 
SHLD2
FAM35A
 as NHEJ-promoting factors and antagonists of HR in BRCA1-defective cells. 324 
This study also identified a third component, RINN1/SHLD3
CTC-534A2.2
 that is proposed to 325 
serve as a molecular bridge from RIF1 to MAD2L2 and SHLD1/2. 326 
 327 
While it seems possible that Shieldin loss contributes to HR restoration in BRCA1-deficient 328 
cells through effects on both resection and on BRCA2/RAD51 loading, the relative 329 
importance of these mechanisms needs further investigation. We note that more extensive 330 
and possibly faster resection in the absence of Shieldin might enhance BRCA2/RAD51 331 
loading. Alternatively, or in addition, Shieldin
 
might serve as a physical barrier to 332 
BRCA2/RAD51 loading at dsDNA/ssDNA junctions in BRCA1-deficient cells Ð perhaps 333 
through it being tethered to DSB-flanking chromatin via the 53BP1/RIF1/MAD2L2 complex 334 
allowing interactions between the C-terminus of distal SHLD2
FAM35A
 and ssDNA (see Fig 7f 335 
for a model, and Supplementary Fig 7e for SHLD2
FAM35A 
domain function summary). 336 
Nevertheless, we found that overexpression of the SHLD2
FAM35A
 N- but not the C-terminus 337 
confers olaparib hypersensitivity to BRCA1/FAM35A double knockout cells, suggesting that 338 
at least in this context, chromatin binding by SHLD2
FAM35A
 plays a dominant role in 339 
restricting HR. By contrast, we found that both the SHLD2
FAM35A
 N- and C-termini are 340 
important for IR resistance (in BRCA1-proficient cells). As IR sensitivity in Shieldin-341 
deficient cells likely reflects impaired NHEJ, we speculate that Shieldin potentiates NHEJ by 342 
restricting DSB resection as well as by assembling with other NHEJ-promoting factors to 343 
tether DSB ends together to facilitate their juxtaposition and repair. 344 
 345 
Notably, we have found that SHLD1
C20orf196
 or SHLD2
FAM35A
 inactivation confers enhanced 346 
cisplatin sensitivity to BRCA1-null or BRCA1-proficient cells. Such sensitivity probably 347 
does not reflect the roles for Shieldin in promoting NHEJ, restricting DNA-end resection or 348 
antagonising BRCA1-mediated BRCA2/RAD51 loading because, in our hands, 53BP1 loss 349 
does not have pronounced effects on cisplatin sensitivity. Intra-strand DNA crosslinks (ICLs) 350 
generated by cisplatin and other compounds are detected and repaired by the Fanconi anemia 351 
(FA) pathway, with a key FA protein being FANCD2, which forms foci at sites of these 352 
lesions
44
. We have observed that following cisplatin treatment, FANCD2 foci were more 353 
pronounced in cells in which SHLD1
C20orf196
 or SHLD2
FAM35A
 was inactivated. It will thus be 354 
of interest to determine if Shieldin Ð like MAD2L2, which (with REV3L) functions as a 355 
regulatory subunit of the trans-lesion DNA synthesis (TLS) polymerase Pol zeta, and whose 356 
biallelic inactivation has been associated with FA
45-47
 Ð might also promote ICL repair via 357 
TLS mechanisms. 358 
 359 
Finally, based on our findings, it will be interesting to evaluate SHLD1/2 expression in 360 
tumour biopsies from patients, establish whether this information can be used in patient 361 
stratification for PARP-inhibitor therapies, and determine whether SHLD1/2 expression 362 
changes arise in patients whose BRCA1-deficient cancers develop resistance after PARP-363 
inhibitor treatment. In this regard, we note that if down-regulation of Shieldin components in 364 
BRCA1-deficient cancers does confer clinical resistance, this might allow alternative 365 
treatments, such as ones based on platinum compounds. 366 
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 537 
Figure legends 538 
Figure 1. CRISPR-Cas9 screens identify suppressors of PARP-inhibitor sensitivity in 539 
BRCA1-mutant cells. a, Schematic of screen procedure. b, MAGeCK analysis of guide 540 
enrichments following specified drug treatments; false discovery rate (FDR) of 0.1 indicated 541 
by dotted line; n=3 technical replicates per drug treatment. c, siRNA mediated verification of 542 
hits in clonogenic survival assays; lower panels show area under the curve (AUC); n=3 543 
independent experiments d, De novo Cas9 mediated knockout (ko) verification and 544 
complementation for FAM35A in clonogenic survival assays (multiple ko clones are shown 545 
in AUC); n=4 independent experiments except FAM35Ako(#14) (n=2), FAM35Ako(#40) 546 
(n=3), BRCA1ko/FAM35Ako(#34) (n=2), and BRCA1ko/FAM35Ako(#2) +FAM35A (n=3).  547 
e, As (d) but for C20orf196; n=3 independent experiments except BRCA1ko/C20orf196ko + 548 
C20orf196 (n=2). c-e Bars represent mean ± SEM, one-way Anova; *p<0.05, **p<0.01, 549 
***p<0.001, ****p<0.0001, ns=not significant (p≥0.05). Individual data points are plotted 550 
over bars, and statistical source data including the precise p values can be found in 551 
Supplementary Table 5. 552 
 553 
Figure 2. FAM35A and C20orf196 domains, interactions and IRIF formation. a, 554 
FAM35A and C20orf196 predicted domains and variants used, OB fold (OB), FAM domain 555 
(OB3/FD). b, Recruitment of FAM35A/derivatives GFP-fusions to a chromosomal Lac-556 
operator array via mCherry-LacR-C20orf196. Data shown represent 3 experiments with 557 
quantifications shown in Supplementary Fig 2a. Scale bar 10µm. c, (left and middle panel) 558 
Purified recombinant GST-FAM35A directly interacts with recombinant His-C20orf196. c, 559 
(right panel) Cell extracts expressing GFP-FAM35A/derivatives and HA-C20orf196 analysed 560 
by co-immunoprecipitation and immunoblotting. d, V5-FAM35A co-immunoprecipitates 561 
with GFP-MAD2L2; interaction with C20orf196 shown in Supplementary Fig 2c. e, 562 
Quantification of inducible GFP-FAM35A (left panel) and GFP-C20orf196 (right panel) 563 
IRIF in gH2AX positive cells 5 h after IR (5Gy) treated with indicated siRNAs. N=4 564 
independent experiments except (left panel) si53BP1 (n=3), siRIF1 and siMAD2L2 (n=2); 565 
and (right panel) siCTRL(n=5), siRIF1(n=3), siFAM35A(n=3). f, As in (e) but for inducible 566 
GFP-FAM35A N-terminus; n=4 independent experiments except siRIF1 (n=3). g, 567 
Endogenous MAD2L2 co-immunoprecipitates with GFP-FAM35A N-terminus. e-f, Bars 568 
represent mean ± SEM, one-way Anova; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 569 
ns=not significant (p≥0.05); individual data points plotted over bars. Statistical source data 570 
including the precise p values are shown in Supplementary Table 5. All immunoblots are 571 
representative of two independent experiments; unprocessed scans of immunoblots are shown 572 
in Supplementary Fig 8. 573 
 574 
Figure 3. FAM35A and C20orf196 promote NHEJ and immunoglobulin class-switch 575 
recombination. a, Random plasmid integration assay. b, FAM35Ako and C20orf196ko cells 576 
were treated with IR and analysed for clonogenic survival, right panel shows AUC. a-b, Bars 577 
represent mean ± SEM, one-way Anova; n=3 independent experiments, except C20orf196ko 578 
in b (n=4), with individual data points plotted over bars; statistical source data can be found 579 
in Supplementary Table 5. c, Schematic representation of class-switch recombination and 580 
chromosomal instability in murine IgM
+
 B cells (germline configuration with Cµ 581 
transcription) induced to express AID and undergo CSR to IgA (switch configuration with Cα 582 
transcription) upon addition of anti-CD40, IL4 and TGF-b. CSR levels are measured as the % 583 
of IgA positive cells after 72 h cytokine stimulation, and DNA fluorescence in situ 584 
hybridization (FISH) is performed using a chromosome 12-specific paint (grey chromosome) 585 
and Igh locus specific probes (red and green spots) for the measurement of chromosomal 586 
instability at the Igh locus upon induction of CSR. d, CSR levels in Fam35Ako and 587 
C20orf196ko CH12-Cas9 cells are reduced compared with wild-type (WT) CH12-Cas9 cells. 588 
Bars represent mean ± SEM, one-way Anova. N=4 independent experiments of 3 clones 589 
except 53BP1ko +cytokine where n=3 of 2 clones, and 53BP1ko -cytokine where n=2 of 2 590 
clones; with individual data points plotted over bars. e, Representative images of Igh 591 
translocation and breaks in aberrant metaphases, quantified in f. f, Quantification of Igh 592 
breaks and translocations in metaphases of the indicated CH12-Cas9 cells. Horizontal bars 593 
represent means, FisherÕs Exact test; n=2 independent experiments except Fam35ako and 594 
C20orf196ko where n=3. For a, b, d and f, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 595 
ns=not significant (p≥0.05); statistical source data including the precise p values for these 596 
panels can be found in Supplementary Table 5. 597 
 598 
Figure 4. FAM35A and C20orf196 promote telomere-mediated fusions and limit DNA-599 
end resection. a, Schematic of TRF2ts experimental setup. b, shRNA depletion of FAM35A 600 
(left panel) or C20orf196 (right panel) reduces un-capped telomere-mediated chromosome 601 
fusions. Bars represent means. The experiments were performed twice with ≥1300 602 
chromosomes counted per condition, and individual data points plotted over bars; source data 603 
can be found in Supplementary Table 5. c, FAM35Ako and C20orf196ko RPE1 cells labelled 604 
with BrdU (10µM) for 48 h then treated with 1µM camptothecin (CPT) for 1 h, pre-extracted, 605 
fixed and stained for BrdU under non-denaturing conditions to visualise ssDNA. Box and 606 
whisker plot with centre line at median, box limits at 25
th
/75
th
 centiles and whiskers 607 
±1.5xIQR; one-way Anova; n=3 independent experiments. d, IR-induced pRPA(S4/8) is 608 
enhanced in MEFs due to Fam35a or C20orf196 silencing. Bars represent means. The 609 
experiments were performed twice with individual data points plotted over bars; source data 610 
can be found in Supplementary Table 5. e, RPE1-FAM35Ako or -C20orf196ko cells display 611 
hyper DNA-end resection (cells treated with 1µM camptothecin for 1h). Representative 612 
images from 3 independent experiments. Scale bar 10µm. f, RPE1-FAM35Ako or -613 
C20orf196ko cells display BLM and CtIP dependent markers of excessive DNA-end 614 
resection. Box and whisker plot with centre line at median, box limits at 25
th
/75
th
 centiles and 615 
whiskers ±1.5xIQR; one-way Anova; n=3 independent experiments. g, Enhanced BLM 616 
accrual in FAM35Ako and C20orf196ko compared with wild-type (WT) RPE1 cells fixed 617 
and stained 2 h after laser micro-irradiation. Representative images shown in left panel and 618 
quantification in right panel. Scale bar 10µm. Box and whisker plot with centre line at 619 
median, box limits at 25
th
/75
th
 centiles and whiskers ±1.5xIQR; one-way Anova; n=3 620 
independent experiments. For c, f and g, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 621 
ns=not significant (p≥0.05); statistical source data including the precise p values can be found 622 
in Supplementary Table 5. 623 
 624 
Figure 5. FAM35A OB folds mediate ssDNA interaction and is required for IR 625 
resistance. a, Schematic of FAM35A with residues W489/W640 mutated to A (top panel). 626 
Predicted 3D structure of wild-type FAM35A with W489 and W640 positions (lower left 627 
panel). FAM35A W489/W640 promote efficient ssDNA binding in cellular extracts (lower 628 
right panel). b, Alignment of yRPA1 with FAM35A C-terminus; amino acids critical for 629 
yRPA1 ssDNA binding and the corresponding amino acid residues in FAM35A are boxed. c, 630 
EMSAs on native (non-denaturing) gels with 10nM ssDNA or dsDNA, and the indicated 631 
purified, bacterially expressed FAM35A C-terminus or W489/W640A mutant in µM. d, 632 
Inducible GFP-FAM35A W489/W640A fails to efficiently form IRIF (12 h after 5Gy of IR). 633 
Scale bar 10µm. Representative images from 3 independent experiments. e, FAM35Ako 634 
RPE1 cells complemented with FAM35A derivatives in clonogenic survival assays; right 635 
panel shows AUC. f, Overexpression of FAM35A N-terminus but not C-terminus or full-636 
length FAM35A sensitises wild-type cells to IR in clonogenic assays; right panel shows 637 
AUC. e-f, Bars represent mean ± SEM, one-way Anova; *p<0.05, **p<0.01, ***p<0.001, 638 
****p<0.0001, ns=not significant (p≥0.05); n=3 independent experiments except group 2 and 639 
4 in e (n=2), with individual data points plotted over bars; statistical source data including the 640 
precise p values can be found in Supplementary Table 5. All immunoblots are representative 641 
of two independent experiments; unprocessed scans of immunoblots are shown in 642 
Supplementary Fig 8. 643 
 644 
Figure 6. FAM35A or C20orf196 loss restores HR in BRCA1-deficient cells. a, 645 
Quantification of GFP-FAM35A (left panel) and GFP-C20orf196 (right panel) IRIF in U2OS 646 
cells after BRCA1 or BRCA2 depletion (5 h after 5Gy). Bars represent mean ± SEM, one-647 
way Anova; n=3 independent experiments, except FAM35A siCTRL (n=4), FAM35A 648 
siBRCA2 (n=2), and C20orf196 siCTRL (n=5); with individual data points plotted over bars. 649 
b, Quantification of 53BP1 and inducible GFP-FAM35A IRIF in U2OS cells with or without 650 
BRCA1 depletion (5Gy, indicated time points). Bars represent mean ± SEM, one-way 651 
Anova; n=4 independent experiments, except 53BP1 1.5h siCTRL (n=2), 53BP1 1.5h 652 
siBRCA1 and 53BP1 16h siCTRL (n=3), FAM35A 1.5h siCTRL (n=5); with individual data 653 
points plotted over bars. c, Representative images (left panel) and quantification (right panel) 654 
of RAD51 IRIF (5.5 h after 5Gy) in Cyclin A (CycA) positive RPE1ko cell lines as indicated. 655 
Bars represent mean ± SEM, one-way Anova; n=3 independent experiments, with individual 656 
data points plotted over bars. Scale bar 10µm. d, FAM35A/C20orf196 loss restore BRCA2 657 
recruitment 2 h after laser-induced DNA-damage sites in BRCA1-null cells (for quantification 658 
see Supplementary Fig 6e). Scale bar 10µm. e, HR assay in U2OS-TLR cells treated with 659 
indicated siRNAs (for gating strategy see Supplementary Fig 6f). Bars represent mean ± 660 
SEM, one-way Anova; n=4 independent experiments, with individual data points plotted over 661 
bars. f, Formation of spontaneous chromosomal aberrations in BRCA1ko cells is alleviated 662 
by FAM35A/C20orf196 inactivation. Representative images of metaphase spreads shown, 663 
and quantified in graph; bars represent means, n=2 independent experiments except 664 
FAM35Ako and C20orf196ko (n=1), with individual data points plotted over bars. g, 665 
Olaparib clonogenic survival assay with indicated RPE1ko and complemented cell lines. Bars 666 
represent mean ± SEM, one-way Anova; n=4 independent experiments, except group 4 and 5 667 
(n=3) and group 3 (n=2); AUC is shown in Supplementary Fig 6g. For a-c and e, *p<0.05, 668 
**p<0.01, ***p<0.001, ****p<0.0001, ns=not significant (p≥0.05); statistical source data 669 
including the precise p values can be found in Supplementary Table 5. 670 
 671 
Figure 7. FAM35A or C20orf196 loss correlates with PARP inhibitor resistance in 672 
cancers. a, Schematic of in vivo PDX study (top panel). Heat map generated from mRNA-673 
sequencing showing scaled expression levels of indicted genes from corresponding PDX 674 
samples (lower panel); n=6, 5, 7, 8 mice for cohorts 1-4 respectively. b, Expression of 675 
C20orf196/FAM35A in breast and ovarian cancer PDXs derived from BRCA1-deficient 676 
tumours. y-axis: log2 transcript per million. Lines represent mean ± SEM; n=12, 4, 15, 1 for 677 
SHLD1-high, SHLD1-low, SHLD2-high, SHLD2-low groups respectively; two-tailed 678 
unpaired student t-test; ***p=0.0003. Statistical source data for PDXs can be found in 679 
Supplementary Table 5 and methods. c-d, Clonogenic survival assay after IR (c) or cisplatin 680 
treatment (d) in the indicated RPE1ko cell lines with AUC shown in Supplementary Fig 7b 681 
and 7c, respectively. Data shown represent mean ± SEM (n = 3 independent experiments 682 
except for group 7 in c and group 7 in d where n = 2) e, Loss of FAM35A/C20orf196 leads to 683 
increased cisplatin-induced FANCD2 foci. Bars represent mean ± SEM, one-way Anova; 684 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns=not significant (p≥0.05); n=4 685 
independent experiments, with individual data points plotted over bars; statistical source data 686 
can be found in Supplementary Table 5. Scale bar 10µm. f, Proposed model for the action of 687 
SHLD1/2 in DSB repair in the presence or absence of functional BRCA1. 688 
 689 
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Supplementary Figure 1 
Whole Genome CRISPR screen data and validation studies!
a,	 Schematic	 of	 the	 one	 vector	 lentiviral	 GeCKOv2	 system.	b,	 Histograms	 of	 sgRNA	 representation	 of	
GeCKOv2	(GKv2)	library	A	(left	panel)	and	B	(right	panel).	Inset:	cumulative	distribution	of	sequencing	
reads.	 The	 number	 of	 sequencing	 reads	 for	 the	 10th	and	 90th	sgRNA	 percentiles	 are	 indicated	 by	 the	
dashed	 vertical	 blue	 lines	 and	 text	 labels.	 The	 representation	 of	 sgRNAs	 is	 indicated	 by	 the	 fold-
difference	between	the	10th	and	90th	percentile.	c,	Representative	surviving	clones	after	treatment	with	
PARP	 inhibitors,	 representative	 of	 2	 independent	 experiments.	 Top	 panel:	 naïve,	 un-transduced	
SUM149PT	cells;!bottom	panel:	GeCKOv2	library-transduced	cells.	d,	Distributions	of	sgRNA	frequencies	
arising	in	different	conditions;	Box	and	whisker	plot	with	centre	line	at	median,	box	limits	at	25th/75th	
centiles	 and	whiskers	±1.5xIQR;	n=3	 technical	 replicates.	e,	 sgRNA	enrichments	 after	 treatments	with	
the	 indicated	 drugs;	 each	 dot	 represents	 one	 sgRNA,	 with	 coloured	 dots	 representing	 the	 indicated	
target	genes.	f,	Verification	of	BRCA1	mutant	SUM149PT,	BRCA1ko	RPE1	and	siRNAs	and	shRNAs	used	
in	 this	 paper,	 by	 immunoblot	 or	 RT-qPCR	 (bars	 represent	 means;	 one	 experiment	 performed	 in	
triplicates).	 g,	 Clonogenic	 survival	 assay	 using	 the	 indicated	 siRNAs	 in	 BRCA1-proficient	 cells	 (WT);	
lower	 panel	 shows	AUC.	 Bars	 represent	mean	±	 SEM,	 one-way	Anova;	 *p<0.05,	 **p<0.01,	 ***p<0.001,	
****p<0.0001,	 ns=not	 significant	 (p≥0.05);	 n=3	 independent	 experiments,	 with	 individual	 data	 points	
plotted	over	bars;	statistical	source	data	 including	the	precise	p	values	can	be	found	in	Supplementary	
Table	 5.	 h,	 Genotypes	 of	 human	 knockout	 clones	 used	 in	 this	 work	 confirmed	 by	 Topo-cloning	 and	
Sanger	sequencing.	i,	Cell	cycle	profiles	of	cells	transfected	with	the	indicated	siRNAs	used	in	this	work	
(bars	represent	means	derived	from	two	independent	experiments).	All	immunoblots	are	representative	
of	two	independent	experiments;	unprocessed	scans	of	immunoblots	are	shown	in	Supplementary	Fig	8.		
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Supplementary Figure 2 
C20orf196/FAM35A interactions and localisation to DNA damage sites  
a,	 Co-localisation	 quantification	 of	 FAM35A/derivatives	 GFP-fusions	 with	 mCherry-LacR-C20orf196.	
Horizontal	bars	represent	means,	one-way	Anova;	*p<0.05,	**p<0.01,	***p<0.001,	****p<0.0001,	ns=not	
significant	(p≥0.05);	n=3	independent	experiments;	statistical	source	data	including	the	precise	p	values	
can	 be	 found	 in	 Supplementary	 Table	 5.	 b,	C-terminus	 of	 FAM35A	 interacts	 with	 C20orf196	 in	 cells	
(without	normalisation).	 c,	 Immunoprecipitation-mass	 spectrometric	 analysis	of	protein	 interactors	of	
GFP-C20orf196	 or	 GFP-FAM35A	 (MAD2L2	 is	 detected	 in	 both;	 far	 left	 and	 middle	 left	 panels).	 GFP-
C20orf196	 co-immunoprecipitates	 with	 Flag-MAD2L2	 in	 HEK293	 cells	 (middle	 right	 IB	 panel).	
Endogenous	MAD2L2	co-immunoprecipitates	with	GFP-FAM35A	and	GFP-C20orf196	(far	right	IB	panel)	
in	HEK293	cells.	d,	Live-cell	 imaging	of	GFP-FAM35A	or	GFP-C20orf196	transiently	expressed	in	U2OS	
cells	stably	expressing	RFP-53BP1.	Recruitment	of	GFP-FAM35A	and	GFP-C20orf196	to	laser	tracks	was	
visible	30	min	after	 laser	micro-irradiation;	 representative	 image	 from	3	 independent	 experiments.	e,	
GFP-FAM35A	 and	 GFP-FAM35A	 N-terminus	 co-localise	 with	 53BP1	 in	 IRIF	 by	 super-resolution	
microscopy;	histogram	of	n=11	cells	per	condition.	f,	Depletion	of	FAM35A	or	C20orf196	does	not	affect	
53BP1	 IRIF	 (U2OS	 cells).	 g,	 as	 in	 f	 but	 for	 MAD2L2	 IRIF.	 Bars	 represent	 means	 derived	 from	 2	
independent	 experiments,	 with	 individual	 data	 points	 plotted	 over	 bars.	 h,	 Depletion	 of	 FAM35A	 or	
C20orf196	 does	 not	 affect	 MAD2L2	 protein	 levels.	 All	 immunoblots	 are	 representative	 of	 two	
independent	experiments;	unprocessed	scans	of	immunoblots	are	shown	in	Supplementary	Fig	8.	
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Supplementary Figure 3 
DNA damage response and IRIF factor dependencies of FAM35A and C20orf196 
a,	Minimal	 variation	 of	 doxycycline	 induced	GFP-FAM35A	 (U2OS)	 and	GFP-C20orf196	 (RPE1)	 in	 cells	
treated	 with	 the	 indicated	 siRNAs.	 Immunoblots	 shown	 are	 representative	 of	 two	 independent	
experiments	with	unprocessed	scans	of	immunoblots	in	Supplementary	Fig	8.	b,	Representative	images	
of	GFP-FAM35A	(left	panel)	and	GFP-C20orf196	(right	panel)	IRIF	in	gH2AX	positive	cells	quantified	in	
Fig	2e.	Scale	bar	10µm.	c,	Depletion	of	PTIP	does	not	affect	GFP-C20orf196	or	GFP-FAM35A	IRIF.	Bars	
represent	mean	±	SEM,	one-way	Anova;	ns=not	significant	(p≥0.05);	n=3	independent	experiments,	with	
individual	data	points	plotted	over	bars;	statistical	source	data	can	be	found	in	Supplementary	Table	5.	
Scale	bar	10µm.	d,	Camptothecin	induced	GFP-FAM35A	foci.	Scale	bar	10µm.	e,	Representative	images	of	
GFP-FAM35A	 derivatives	 with/without	 pre-extraction	 ±IR;	 d-e	 representative	 of	 2	 independent	
experiments.	Scale	bar	10µm.	 f,	Representative	 images	of	GFP-FAM35A	N-terminus	 IRIF	dependencies	
quantified	in	Fig	2f.	Scale	bar	10µm.		
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Supplementary Figure 4 
FAM35A and C20orf196 directly affect class switch recombination 
a,	Clonogenic	survival	assay	following	IR	treatment	using	wild-type,	Fam35ako	or	C20orf196ko	mouse	
!!
ES	 cells	 (right	 panel	 shows	 AUC).	 Bars	 represent	 means	 ±	 SEM,	 one-way	 Anova;	 n=3	 independent	
experiments,	 with	 individual	 data	 points	 plotted	 over	 bars.	b,	 Genotypes	 of	 CH12-Cas9	 cell	 knockout	
clones	used	CSR	assays	 confirmed	by	Topo-cloning	and	Sanger	 sequencing.	c,	 Flow	cytometry	profiles	
showing	 the	 percentage	 of	 IgA+	 cells	 for	 indicated	 CH12-Cas9	 cell	 clones	 (genotypes)	 after	 3	 days	
stimulation	 with	 anti-CD40,	 IL-4	 and	 TGF-β.	 Cell	 clone	 numbers	 are	 indicated;	 representative	 of	 3	
independent	 experiments.	 d,	 CSR	 assay	 in	 C20orf196ko	 cells	 complemented	 with	 C20orf196.	 Bars	
represent	 means	 ±	 SEM,	 one-way	 Anova;	 n=3	 independent	 experiments,	 with	 individual	 data	 points	
plotted	 over	 bars.	 e,	 CH12-Cas9	 clones	 were	 plated	 at	 50,000	 cells/ml	 and	 counted	 after	 3	 days	
stimulation	 with	 anti-CD40,	 IL4,	 and	 TGF-β.	 Bars	 represent	 means	 ±	 SEM,	 one-way	 Anova;	 n=3	
independent	 experiments,	 with	 individual	 data	 points	 plotted	 over	 bars.	 For	 a,	 d	 and	 e,	 *p<0.05,	
***p<0.001,	 ****p<0.0001,	 ns=not	 significant	 (p≥0.05);	 statistical	 source	 data	 including	 the	 precise	 p	
values	can	be	found	in	Supplementary	Table	5.	f,	Igh,	α	germ-line	transcripts	(αGLT)	and	Aid	mRNA	were	
quantified	by	 semi-quantitative	RT–PCR	using	2.5-fold	 serial	dilutions	of	 cDNA	made	 from	CH12-Cas9	
cells	 and	 indicated	 CH12-Cas9	 knockout	 cell	 clones	 after	 2	 days	 stimulation	with	 anti-CD40,	 IL4,	 and	
TGF-β.	Hprt	 was	 used	 as	 a	 control	 for	 transcript	 expression.	 Immunoblots	 are	 representative	 of	 two	
independent	experiments	with	unprocessed	scans	of	immunoblots	in	Supplementary	Fig	8.	
!
!!
!
Supplementary Figure 5 
Effects of FAM35A and C20orf196 on telomere fusions, DNA binding and DNA-end resection  
a,	Telomere	fusion	assay	as	shown	in	Fig	4b	but	complemented	with	shRNA	resistant	human	C20orf196.	
!!
Bars	represent	means	derived	from	2	independent	experiments	with	≥1300	chromosomes	counted	per	
condition,	and	individual	data	points	plotted	over	bars;	source	data	can	be	found	in	Supplementary	Table	
5.	b,	qRT-PCR	of	mouse	 (left)	 and	human	 (right)	 transcripts	 in	MEFs.	Bars	 represent	means	 from	one	
experiment	performed	 in	 triplicates.	c,	FRAP	of	GFP-RPA1	 in	stably	expressing	U2OS	cells,	depleted	of	
FAM35A	or	C20orf196.	Points	represent	mean	±	95%	confidence	intervals;	residence	time	calculated	as	
previously	 described50;	 n=28	 independent	 experiments	 (siCTRL),	 n=22	 (siFAM35A)	 and	 n=30	
(siC20orf196).	 d,	 Structure	 of	 yeast	 RPA1	 (yRPA1)	 with	 ssDNA.	 e,	 Coomassie	 stained	 SDS-PAGE	 gel	
showing	the	bacterial	purified	FAM35A	variants	used	in	EMSAs.	Immunoblots	are	representative	of	two	
independent	 experiments	 with	 unprocessed	 scans	 of	 immunoblots	 in	 Supplementary	 Fig	 8.	 f,	 GFP-
FAM35A	W489/W640A	is	able	to	interact	with	mCherry-LacR-C20orf196	in	cells;	representative	of	two	
independent	 experiments,	 scale	 bar	 10µm.	 g,	 Overexpression	 of	 FAM35A	 or	 derivatives	 does	 not	
sensitise	 wild-type	 cells	 to	 olaparib,	 adjacent	 panel	 shows	 AUC.	 Bars	 represent	 means	 from	 one	
experiment	performed	in	triplicates.		
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Supplementary Figure 6 
FAM35A and C20orf196 functions relating to homologous recombination 
a,	 Representative	 images	 for	 quantifications	 of	 GFP-FAM35A	 presented	 in	 Fig	 6a;	 scale	 bar	 10µm.	b,	
Representative	images	for	quantifications	presented	in	Fig	6b;	scale	bar	10µm.	c,	Representative	images	
of	FAM35A	and	C20orf196	effects	on	DNA-end	resection	in	wild-type	and	BRCA1ko	cells	as	measured	by	
RPA	 nuclear	 intensity	 (after	 pre-extraction)	 following	 camptothecin	 treatment	 in	 the	 indicated	
genotypes,	 quantified	 in	 Supplementary	 Fig	 6d;	 scale	 bar	 10µm.	 d,	 Quantification	 of	 nuclear	 RPA	
intensity;	 n=5	 independent	 experiments,	 except	 WT	 siAbraxas	 and	 BRCA1ko	 siCtIP	 (n=2)	 and	
BRCA1ko/FAM35Ako	 (n=4),	with	 individual	 data	 points	 plotted	 over	 bars.	e,	Quantification	 of	 BRCA2	
accrual	at	laser	micro-irradiated	RPE1	cells	with	the	indicated	genotypes	for	the	representative	images	
presented	 in	 Fig	 6d.	 n=3	 independent	 experiments,	 with	 individual	 data	 points	 plotted	 over	 bars.	 f,	
Gating	strategy	employed	for	TLR	assay.	g,	AUC	for	clonogenic	survival	assay	presented	 in	Fig	6g.	N=4	
independent	experiments,	except	BRCA1ko/FAM35Ako	+FAM35A	and	+N-terminus	where	n=3,	and	+C-
terminus	where	 n=2;	with	 individual	 data	 points	 plotted	 over	 bars.	 h,	 FAM35A	 and	 53BP1	 effects	 on	
olaparib	 resistance	 in	 BRCA1ko	 cells	 are	 not	 additive	 as	measured	 by	 clonogenic	 survival	 assay	 (left	
panel),	AUC	(right	panel).	N=4	independent	experiments,	except	BRCA1ko/53BP1ko/FAM35Ako	where	
n=2;	with	individual	data	points	plotted	over	bars.	In	d,	e,	g	and	h,	bars	represent	mean	±	SEM,	one-way	
Anova;	*p<0.05,	**p<0.01,	***p<0.001,	****p<0.0001,	ns=not	significant	(p≥0.05);	statistical	source	data	
including	the	precise	p	values	can	be	found	in	Supplementary	Table	5.	
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Supplementary Figure 7 
Tumour growth curves in mice and cell sensitivities of SHLD mutant cells to DNA damaging agents 
a,	 Tumour	 growth	 curves	 of	 PDX	mice	 cohorts	 treated	with	 vehicle	 or	 olaparib	 in	 Fig	 7a;	 points	 are	
means,	 with	 lines	 representing	 s.d.	 for	 each	 of	 cohorts	 1-4.	 b,	 AUC	 for	 clonogenic	 survival	 assay	
presented	 in	Fig	7c.	N=3	 independent	experiments	except	BRCA1ko	and	C20orf196ko	where	n=4,	and	
BRCA1ko/FAM35Ako	 where	 n=2.	 c,	 AUC	 for	 clonogenic	 survival	 assay	 presented	 in	 Fig	 7d.	 N=3	
independent	 experiments	 except	 WT	 where	 n=6	 and	 BRCA1ko/FAM35Ako	 where	 n=2.	 b-c	 Bars	
represent	mean	±	SEM,	one-way	Anova;	*p<0.05,	**p<0.01,	***p<0.001,	****p<0.0001,	ns=not	significant	
(p≥0.05).	Individual	data	points	plotted	over	bars;	statistical	source	data	including	the	precise	p	values	
can	be	found	in	Supplementary	Table	5.	d,	GFP-FAM35A	foci	are	not	affected	by	depletion	of	FANCD2;	
representative	 images	 (left	 panel)	 and	 quantification	 (right	 panel).	 Bars	 represent	 means	 from	 2	
independent	 experiments,	with	 individual	 data	 points	 plotted	 over	 bars.	 Scale	 bar	 10µm.	e,	 Graphical	
summary	of	SHLD2FAM35A	domains	and	their	function.		
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Supplementary Figure 8  
Uncropped blots  
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Supplementary Figure 8 continued 
Uncropped blots  
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Methods 1 
CRISPR-Cas9 screen. Performed using genome-scale (GeCKO) v2.0
20
. SUM149PT cells 2 
were transduced at multiplicity of infection (MOI) of 0.3 and 250-fold coverage of the 3 
library. Cells were then selected with puromycin for 7 days prior to treatment with 3 different 4 
PARPi for a further 14 days. ICÕs used were; Olaparib IC95-2 µM, BMN673 IC95-5 nM, 5 
AZD2461 IC70-4 µM. Surviving clones from each condition were collected, genomic DNA 6 
(gDNA) isolated (Blood & Cell Culture DNA Midi Kit, Qiagen) and subjected to PCR with 7 
Illumina-compatible primers, followed by Illumina sequencing. Genes enriched or depleted 8 
in the inhibitor-treated samples were determined by the software package MAGeCK version 9 
0.5.5 (see commands in the section of ÒCode availabilityÓ).  10 
 11 
Cell culture. U2OS, U2OS-derived, HEK293, HEK293T-LentiX cells were cultured as in
39
. 12 
RPE1 p53
 
null FRT
48
 and RPE1 p53 null FRT-derived cells were cultured in F-12 (HamÕs F-13 
12; Sigma-Aldrich) supplemented with 17 ml NaHCO3 7.5% per 500ml (Sigma-Aldrich). All 14 
media was supplemented with 10% (v/v) foetal bovine serum (FBS; BioSera), 100 U/ml 15 
penicillin, 100 µg/ml streptomycin (Sigma-Aldrich) and 2 mM L-glutamine. SUM149PT 16 
cells were cultured in Ham's F12 Nutrient Mixture (ThermoFisher) supplemented with 5% 17 
(v/v) FBS (BioSera), 10 mM HEPES, 1 µg/ml hydrocortisone, 5 µg/ml insulin, antibiotic as 18 
described above. For maintenance and selection of RPE1 FRT p53 null or U20S Trex cells 19 
stably expressing GFP or GFP-tagged constructs, 2 µg/ml blasticidin (Sigma-Aldrich) and 0.5 20 
mg/ml G418 (Invitrogen) were used. U2OS-TLR were cultured as in
39
. In addition to RPE1 21 
p53 null FRT-derived cells, U20S Trex cells stably expressing inducible constructs were 22 
cultured with 1 µg/ml doxycycline (Sigma-Aldrich) for 24-48h to induce expression of GFP 23 
constructs. All cells were originally obtained from the ATCC cell repository and routinely 24 
tested to be mycoplasma free. The U2OS and RPE1 cell lines were recently authenticated 25 
using Affymetrix SNP6 copy number analysis. Trf2-/-;p53-/-;TRF2(Ile468Ala) MEFs 26 
(TRF2ts MEFs) as described previously
33, 49
. CH12F3 (CH12)
29
 and CH12-Cas9 cell lines 27 
were cultured in RPMI 1640 supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml 28 
streptomycin, 50µM 2-mercaptoethanol, 1xMEM non-essential amino acids, 1mM sodium 29 
pyruvate and 10mM HEPES. 30 
 31 
Generation of human stable cell lines and knockouts. U2OS Trex or RPE1 p53 null FRT-32 
derived cells stably expressing inducible GFP-tagged constructs, were generated by 33 
transfection of pcDNA5/FRT/TO-neo containing the GFP-tagged construct and pOG44 (1:4 34 
respectively). Selection began at 48 h using 0.5 mg/ml G418 (Invitrogen). Knockouts were 35 
generated in RPE1 p53 null cells by transfecting an ÔAll-in-oneÕ plasmid
48
. Single-cell sorting 36 
by GFP expression was done using MoFlo (Beckman Coulter). Single clones were expanded, 37 
genomic DNA extracted and screened by PCR, TOPO-cloning and sequencing. Validated 38 
mouse Embryonic Stem Cell (mESC) knockouts of Fam35a and C20orf196 were obtained 39 
from Haplobank (www.haplobank.at).  40 
 41 
Plasmids and cloning. See Supplementary Table 3.  42 
 43 
siRNA and plasmid transfection. siRNAs were obtained from MWG or IDT and transfected 44 
using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturerÕs protocol. 45 
Plasmid transfections were carried out using TransIT-LT1 (Mirus Bio) according to the 46 
manufacturerÕs protocol. For siRNA and DNA co-transfections, plasmids were transfected 8h 47 
after siRNA treatment. See Supplementary Table 4.  48 
 49 
Random plasmid integration assay. Performed as previously described
27
. 50 
 51 
DNA-damage induction using chemical agents, ionizing radiation and laser micro-52 
irradiation. Performed as previously described
39
. 53 
 54 
FRAP and association kinetics. Performed as previously described
50
. 55 
 56 
TLR assays. The Traffic Light Reporter (TLR) assay and the constructs used herein have 57 
been described in detail previously
38, 39
.  58 
 59 
Cell-cycle profiling. Performed as previously described
39
. 60 
 61 
Clonogenic survival assays. Performed as previously described
27,39
. 62 
 63 
Whole cell extracts and immunoblotting. Were performed as previously described
39
. For 64 
detection of phospho-RPA (pS4/S8-RPA2), lysates were prepared by scraping cells in 2xSDS 65 
buffer followed by SDS-PAGE using 4-12% Bis-Tris gel (Invitrogen), and immunoblotting 66 
was done using SuperSignal West Pico PLUS (Thermo Scientific). IRDye800CW- and 67 
IRDye680-labelled secondary antibody was used for detection on the Odyssey Infrared 68 
imager (LI-COR). Quantification of blots was performed using ImageJ. All protein 69 
concentrations were determined using a BCA assay (Pierce). All antibodies are listed in 70 
Supplementary Table 2.  71 
 72 
Immunoprecipitation. All immunoprecipitation procedures performed twice as previously 73 
described
39
. For co-immunoprecipitation shown in Fig 2d (FAM35A), 293T cells were co-74 
transfected with pMSCV-blas-eGFP-MAD2L2 and either pLX304-blast-V5-Empty or 75 
pLX304-V5-FAM35A. 72h post-transfection cells were exposed to 25Gy IR followed by 3h 76 
recovery. GFP-Trap_MA beads (ChromoTek) were used, and immunoprecipitation was 77 
performed according to the manufacturerÕs protocol. For C20orf196 (Supplementary Fig 2c), 78 
293T cells were co-transfected with pMSCV-blas-3xFlag-hMAD2L2 and either pcDNA5.1-79 
GFP or pcDNA5.1-GFP-C20orf196. 72h post-transfection, cells were exposed to 25Gy IR 80 
followed by 3h recovery. After washing with cold PBS, cells were lysed in 1 ml lysis buffer 81 
(50mM Tris HCl pH7.4; 150mM NaCl; 1mM EDTA; 1% Triton X-100) supplemented with 82 
the same inhibitors as above. After 30min incubation on ice followed by centrifugation 83 
(16,000g), anti-Flag M2 Magnetic Beads (M8823, Sigma-Aldrich) pre-washed with TBS 84 
(50mM Tris HCl, 150 mM NaCl pH7.4), were added to the lysate and rotated over-night at 85 
4¡C. Immune-complexes were eluted by 5min boiling. 86 
 87 
DNA pulldown experiments. Procedures were described in detail in
39
 using oligos with the 88 
sequence: 89 
5ÕBiosG/ATCGCATTGGCATTGGCAATGCGATACGACTGATCGAGGGTACTCAGCT90 
AGCTGATTCCGATCGGCTTATTCCGTGTACATACATCGGAT-3Õ (IDT) 91 
 92 
In vitro GST pull-down. Gluathione sepharose beads (GE Healthcare) were washed with 93 
ice-cold PBS and blocked for 30min with PBS supplemented with 10% bacterial lysate (non-94 
induced BL21 cells, lysed using PBS/lysozyme) then resuspended in binding buffer (10mM 95 
Tris pH7.5, 150 mM NaCl, 0.5% NP40, 0.5 mM EDTA, 0.5 % BSA). Purified GST (bacterial 96 
expression), GST-FAM35A (Novus Biologicals), and His-C20orf196 (Creative BioMart) 97 
were added to the beads at 2 pmol and incubated for 30min at 4¡C. Beads were washed 5x 98 
with 10 mM Tris, pH 7.5, 250 mM NaCl, 0.5 % NP40, 0.5 mM EDTA and eluted with 100 99 
mM Tris pH 8, 20 mM reduced glutathione, 120 mM NaCl for 15min rotating at 4¡C. The 100 
eluates were boiled for 5min, loaded on 4-12 % Bis-Tris gel (Invitrogen) and subjected to 101 
western blotting. The blots were probed with the indicated antibodies.  102 
 103 
Recombinant protein purifications and Electrophoretic Mobility Shift Assays (EMSAs). 104 
Wild-type and mutant FAM35A C-terminal domains were purified using the same method. 105 
Harvested cells were lysed by sonication in 50 mM Tris pH 8.0, 5% glycerol, 150 mM NaCl, 106 
2 mM β-mercaptoethanol, 10mM imidazole, protease inhibitor (Roche) and 40 g/ml 107 
deoxyribonuclease I (Sigma). After centrifugation at 30,000g for 30min, supernatant was 108 
loaded onto a gravity column containing Ni-NTA affinity resin (Qiagen) pre-equilibrated 109 
with 50 mM Tris pH 8.0, 5% glycerol, 150 mM NaCl, 2 mM β-mercaptoethanol and 10 mM 110 
imidazole. After washing beads with the same buffer for 10x column volume, protein was 111 
eluted using 50 mM Tris pH 8.0, 5% glycerol, 150 mM NaCl, 2 mM β-mercaptoethanol and 112 
100 mM imidazole. The eluate was dialysed with Q column (GE healthcare) buffer A (20 113 
mM Tris pH 8.0, 50 mM NaCl, 5% glycerol and 2 mM β-mercaptoethanol) and loaded onto a 114 
5 ml Q column. Protein was eluted in a gradient against buffer B (20 mM Tris pH 8.0, 1 M 115 
NaCl, 5% glycerol and 2mM β-mercaptoethanol). Fractions containing FAM35A protein 116 
were collected and further purified by running through Superdex 200 10/300 column (GE 117 
Healthcare) equilibrated in buffer GF (20 mM Tris pH 8, 150 mM NaCl, 5% glycerol and 5 118 
mM DTT). Protein samples during each step of purification were analysed on 4-12% Bis-Tris 119 
gels (Invitrogen). Final purified samples were concentrated and stored at -80
o
C.  Both 120 
forward and reverse 90-bases DNA oligos (IDT) (F: 6-FAM (6-carboxyfluorescein)-121 
ATCGCATTGGCATTGGCAATGCGATACGACTGATCGAGGGTACTCAGCTAGCTG122 
ATTCCGATCGGCTTATTCCGTGTACATACATCGGAT; R:6-FAM- 123 
ATCCGATGTATGTACACGGAATAAGCCGATCGGAATCAGCTAGCTGAGTACCCT124 
CGATCAGTCGTATCGCATTGCCAATGCCAATGCGAT) were dissolved in annealing 125 
buffer (10 mM Tris pH 8.0, 50 mM NaCl and 1 mM EDTA) to a final concentration of 100 126 
µM.  DNA oligo F was used as ssDNA for EMSA. Equal volumes of DNA oligo F and R 127 
were mixed and annealed (heated to 95
o
C for 2min and cooled to 25
o
C over 45min) to 128 
generate dsDNA. Each 20 µl of EMSA reaction contained 10 nM of ssDNA/dsDNA 129 
incubated with different concentrations of proteins in 20 mM Tris-HCl pH 7.5, 50 mM KCl, 130 
5% (v/v) glycerol, 100 µM DTT, 10 µg/ml BSA. Samples were incubated at 37
o
C for 15min 131 
and applied onto a 5% polyacrylamide native gel in 0.5xTBE buffer for electrophoresis at 132 
4
o
C. DNA was visualized by Typhoon 9000 (GE Healthcare).  133 
 134 
GFP-Trap pull down for mass spectrometry. HEK293T cells were cultured in SILAC 135 
media containing either L-arginine and L-lysine, or L-arginine [
13
C6, 
15
N4] and L-lysine 136 
[
13
C6, 
15
N2] (Cambridge Isotope Laboratories) as described previously
51
. Cells were lysed 48h 137 
post-transfection in modified RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 138 
1% NP-40, 0.1% sodium deoxycholate) supplemented with protease, phosphatase inhibitors 139 
and N-ethylmaleimide. Lysates were cleared by centrifugation at 16,000×g for 15min at 4¡C 140 
and protein concentrations were estimated using QuickStart Bradford Protein assay (BioRad). 141 
Per SILAC condition, 20 µl of pre-equilibrated GFP-Trap-A beads (ChromoTek) were added 142 
to 2 mg of lysate and incubated 1h at 4¡C rotating, followed by 3x washes with modified 143 
RIPA buffer. Bound proteins were eluted in NuPAGE¨ LDS Sample Buffer (Life 144 
Technologies) supplemented with 1 mM dithiothreitol, heated at 70 ¼C for 10min and 145 
alkylated with 5.5 mM chloroacetamide at RT. Samples were loaded onto 4-12% gradient 146 
SDS-PAGE gels, proteins were stained using the Colloidal Blue Staining Kit (Life 147 
Technologies) and digested in-gel using trypsin. Peptides were extracted from the gel and 148 
desalted on reversed phase C18 StageTips
52
.  149 
 150 
Mass spectrometry analysis. Peptide fractions were analyzed on a quadrupole Orbitrap 151 
mass spectrometer (Q Exactive Plus, Thermo Scientific) equipped with an EASY-nLC 1000 152 
(Thermo Scientific) as described
53
. Peptide samples were loaded onto C18 reversed phase 153 
columns and eluted with a linear gradient from 8 to 40% acetonitrile containing 0.1% formic 154 
acid for 2h. The mass spectrometer was operated in data dependent mode, automatically 155 
switching between MS and MS2 acquisition. Survey full-scan MS spectra (m/z 300Ð1650) 156 
were acquired in the Orbitrap. The ten most intense ions were sequentially isolated and 157 
fragmented by HCD
54
. Fragment spectra were acquired in the Orbitrap mass analyzer. Raw 158 
data files were analyzed using MaxQuant (development version 1.5.2.8)
55
. Parent ion and 159 
MS2 spectra were searched against a database containing 92,578 human protein sequences 160 
obtained from the UniProtKB released in December 2016 using Andromeda search engine
56
. 161 
Spectra were searched with a mass tolerance of 6 ppm in MS mode, 20 ppm in HCD MS2 162 
mode, strict trypsin specificity and allowing up to three miscleavages. Cysteine 163 
carbamidomethylation was searched as a fixed modification, whereas protein N-terminal 164 
acetylation, methionine oxidation, n-ethylmaleimide modification of cysteines were searched 165 
as variable modifications. The dataset was filtered based on posterior error probability to 166 
arrive at a false discovery rate below 1% estimated using a target-decoy approach
57
. 167 
 168 
Immunofluorescence and microscopy imaging. Confocal imaging for gH2AX, RAD51, 169 
RPA, ssDNA (BrdU), BLM, BRCA2, FANCD2, Cyclin A and GFP (FAM35A and 170 
C20orf196) was performed as described in
39
, for RAD51 and Cyclin A the pre-extraction step 171 
was omitted and cells were permeabilised for 15min in 0.2% Triton X-100 (Sigma) in PBS 172 
after fixation. Super-resolution images were acquired using a Deltavision OMX 3D-SIM 173 
System V3 BLAZE (Applied Precision, a GE Healthcare company) equipped with 3 sCMOS 174 
cameras, 405, 488, 592.5nm diode laser illumination, an Olympus Plan Apo N 60x 1.42NA 175 
oil objective, and standard excitation and emission filter sets. Imaging of each channel was 176 
done sequentially using three angles and five phase shifts of the illumination pattern as 177 
described
58
. Sections were acquired at 0.125 µm z steps. Raw OMX data was reconstructed 178 
and channel registered in SoftWoRx software version 6.5.2 (Applied Precision, a GE 179 
Healthcare company). Voxelwise nearest-neighbour distances were measured for GFP-180 
FAM35A signal relative to 53BP1 signal using a custom script (Butler R) for Fiji 181 
(https://github.com/gurdon-institute/OMX-Spatial-Analysis). The script maps signal volumes 182 
using Kapur's maximum entropy thresholding method
59
 and measures distances using the 183 
exact signed 3D Euclidean distance transform with internal distances set to zero for display 184 
on the histogram. For all images, scale bars = 10µm. 185 
 186 
Multiplex fluorescence in situ hybridisation (M-FISH). Human 24-colour multiplex FISH 187 
(M-FISH) probe preparation and slides treatments followed
60
. For each human cell sample, 188 
10-30 metaphases were karyotyped based on the M-FISH classification and DAPI-banding 189 
pattern. FISH on metaphases spreads using BAC probes was performed as previously 190 
described
61
 and counted manually. For class-switch recombination (CSR) assays, DNA FISH 191 
on metaphases spreads was performed as previously described
61
 and counted manually. At 192 
least 470 metaphases were evaluated per genotype, using at least 2 independent clones for 193 
each condition. For telomere uncapping, cell harvesting, preparation of metaphase spreads 194 
and telomere FISH with an Alexa488-(CCCTAA repeat) peptide nucleic acid custom probe 195 
(PN-TC060-005, Panagene/Eurogentec), metaphase chromosome analysis was done as 196 
described previously
6
. These data represent 2 independent experiments, ≥1300 chromosomes 197 
for each condition, counted manually after blinding the genotypes.  198 
 199 
Telomere fusion assays: MEFs viral transduction. Cells were transduced as before
49
 with 200 
pLKO-puro shRNA lentiviruses obtained from the MISSION shRNA library (Sigma), against 201 
mouse genes as described or left untransduced (ÔemptyÕ). Assessment of telomere NHEJ. 202 
TRF2ts MEFs were grown for 24h at the non-permissive temperature of 39¡C to inactivate 203 
TRF2 and induce NHEJ-dependent chromosome end-to-end fusions because of telomere 204 
uncapping.  205 
 206 
Class-switch recombination assays: CH12 and CH12-Cas9 cell lines. The CH12-Cas9 cell 207 
line was generated by transducing CH12-Cas9 cells made using spin-infect with lentivirus 208 
particles packaged in HEK293T. Plasmids: pKLV2-EF1aBsd2Acas9-W, pxPAX2 (Addgene 209 
#12260), VSV-G and pMD2.G (Addgene #12259). Blasticidin selection (10 µg/ml) started 210 
48h after transduction for one week. sgRNA expression plasmids for class-switch 211 
recombination assays. sgRNAs were used to target Fam35a, C20orf196 and Mad2l2/Rev7 212 
mouse genes (2 sgRNAs per target gene, sequences listed in Supplementary Table 4. sgRNAs 213 
were cloned into pKLV-flipped U6gRNA_CCDB_PB_BbsI_PGKpuro2ABFP vector
62
. 214 
Generation of wild-type and knockout CH12-Cas9 cell clones. 53bp1 null CH12 cell 215 
clones (gift from Fred Alt) were as previously described
63
. 12 million CH12-Cas9 cells were 216 
nucleofected with 2.2 µg of each sgRNA-1 and sgRNA-2 and 0.6 µg of piggyBac transposase 217 
expression vector
64
, using an Amaxa Nucleofector, Nucleofector¨ Kit V solution (Lonza) 218 
and program X-001. Two days later, BFP-positive/puromycin-resistant CH12-Cas9 cells 219 
were selected with 3 µg/ml puromycin for one week. Cells were then single cell diluted into 220 
96-well plates, further cultured and screened by PCR and Sanger sequenced using PCR 221 
primers listed in Supplementary Table 4. Class-switch recombination and cell 222 
proliferation assays. CH12 cells were plated at 50,000 cells/ml in complete RPMI 223 
supplemented with anti-CD40 antibody (1 µg/ml, Miltenyi), IL-4 (20 ng/ml, Miltenyi) and 224 
TGF-b (1 ng/ml, R&D Biotech) to induce IgM to IgA switching. After 3 days, cells were 225 
assayed for class-switching by flow cytometry using an IgA-PE antibody (eBiosciences) and 226 
a Canto II analyser (BD Biosciences). Viable cells were counted using a Casy cell counter 227 
(Roche). CSR and proliferation assays were done on: 3xwild-type (WT), 3xFam35a knockout 228 
(Fam35a), 3xC20orf196 knockout (C20orf196), 2x53bp1 knockout (53bp1) and 3xMad2l2 229 
knockout (Mad2l2) in three independent experiments. RT-PCR analysis. Igh, α germ-line 230 
transcripts (αGLT) and Aid mRNA were quantified as previously described
12
. Primers are 231 
listed in Supplementary Table 4. 232 
 233 
Patient-derived tumour xenografts. PDXs were generated and established from consented 234 
breast or ovarian cancer patientsÕ samples as previously described
40
. The research was done 235 
with the appropriate approval by the National Research Ethics Service, Cambridgeshire 2 236 
REC (REC reference number: 08/H0308/178), and by the Vall dÕHebron Hospital Clinical 237 
Investigation Ethical Committee (PR(AG)183/2012). STG201, the PDX model used in this 238 
study, is a BRCA-null model featuring BRCA1 promoter methylation, loss of BRCA1 239 
mRNA and protein expression. We have previously shown its sensitivity in vivo and in PDX 240 
derived cells to PARP inhibitors, including olaparib. STG201 is also linked to deep molecular 241 
and drug sensitivity annotation
40
 and http://caldaslab.cruk.cam.ac.uk/bcape/. All other PDXs 242 
were derived from breast or ovarian tumours from BRCA1-mutation carriers or BRCA1 243 
epigenetic silencing due to promoter hypermethylation
41
. PDX127 did not show any co-244 
expression of BRCA1 but it was low in both FAM35A and C20orf196 expression. None of 245 
the 5 PARPi-sensitive PDXs exhibited low levels of C20orf196, FAM35A or 53BP1 loss nor 246 
BRCA1 hypomorphs. The study was compliant with all relevant ethical regulations regarding 247 
research involving animal use and human participants.   248 
 249 
Generation of acquired drug resistance in vivo. AZD2281 (Olaparib/Lynparza) as a PARP 250 
inhibitor (50mg/kg, 5IW) was administered to immunocompromised tumour bearing mice 251 
upon randomization as previously described (50mg/kg, 5 days/week)
40
. To classify the 252 
response of the subcutaneous implants we modified the RECIST criteria to be based on the % 253 
tumour volume change following continuous olaparib treatment: complete response (CR), 254 
best response≤-95%; partial response (PR), -95%<best response≤-30%; stable disease (SD), -255 
30%<best response≤+20%; progressive disease (PD), % tumour volume change at day 21 of 256 
treatment >+20%. PARPi-resistant PDXs exhibited PD while PARPi-sensitive models 257 
exhibited SD, PR or CR. For STG201, time matched vehicle and olaparib treated samples 258 
were collected 25 days after treatment (PARPi nave PDX) and processed for RNA 259 
extractions and sequencing. A couple of mice in the study were left with continued exposure 260 
to olaparib until tumour regrowth. One of these resistant tumours was serially passaged 126 261 
days after treatment into new host mice (PARPi resistant PDX) and treated with further 262 
vehicle or olaparib. 58 days after treatment the resistance phenotype was confirmed and 263 
samples were collected and processed for RNA-sequencing as described below. Growth 264 
curves show average and standard deviation of at least 5 independent tumour volumes per 265 
trial arm. All experimental procedures were approved by the University of Cambridge 266 
Animal Welfare and Ethical Review Committee and by the Vall dÕHebron Hospital Clinical 267 
Investigation Ethical Committee and Animal Use Committee. RNA-sequencing. RNA was 268 
extracted from all samples using the Qiagen miRNeasy or RNeasy Mini kit (Cat ID, 217004 269 
or 74104) as per manufacturerÕs instructions. Libraries for Illumina sequencing were 270 
prepared using TruSeq Stranded mRNA HT kit or Total RNA Library Prep kit with Ribo-271 
Zero Gold (Cat ID, RS-122-2103 or RS-122-2301, Illumina). 500ng of total RNA with RNA 272 
Integrity Numbers (RINs) above 8 was used for library preparation. Samples were processed 273 
following manufacturerÕs HS (High-Sample) instructions (part# 15031048 Rev. E, Illumina) 274 
with 12 or 15 cycles of PCR used at the Enrichment of DNA Fragments step. All libraries 275 
were quantified using KAPA Library Quantification Kit Illumina ROX Low (Cat ID, 276 
KK4873, KAPA Biosystems) and normalised. Libraries were pooled in equal volumes and 277 
pools were used for clustering on HiSeq4000 sequencing flow cell following manufacturerÕs 278 
instructions. Sequencing was performed using 150bp or 100bp paired-end run type for dual-279 
indexed libraries. Prior to alignment, sequencing quality of the reads was enforced using 280 
Trim Galore! (v0.4.2) http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/. 281 
Then, as described in Callari et al. or Ahdesmaki et al
65
 reads were aligned to a combined 282 
human (hg19) and mouse (mm10) reference genome using STAR (v2.5.2b)
66, 67
. Counts were 283 
assigned to genome features using featureCounts (v1.5.2), whereby the alignment score is 284 
used to discern accurately between reads sourced from human and mouse
68
. Counts from 285 
multiple sequencing runs were merged and then normalised using the edgeR package
69, 70
. 286 
 287 
Code availability A custom FIJI script used in OMX analysis can be found at 288 
https://github.com/gurdon-institute/OMX-Spatial-Analysis. 289 
 290 
The MAGeCK commands used for CRISPR-Cas9 screens were:  291 
mageck test -k counts.csv   -c DMSO -t WC_2461 -n WC_2461  292 
mageck test -k counts.csv   -c DMSO -t WC-673 -n WC-673  293 
mageck test -k counts.csv   -c DMSO -t WC-2281 -n WC-2281  294 
 295 
 296 
Statistics and Reproducibility  297 
Unless stated otherwise Prism v7.0b (GraphPad Software) was used to generate graphs, 298 
perform statistical tests and calculate p values. Error bars, statistical tests and number of 299 
independent repeats (n) are indicated in figure legends with statistical source data including 300 
the precise p values provided in Supplementary Table 5. Statistical tests included two-tailed 301 
Student t-tests, FisherÕs Exact test, and one-way analysis of variance (ANOVA), the latter all 302 
being corrected as recommended for multiple comparisons. Microscopy image analyses were 303 
performed using ImageJ/FIJI or Volocity 6.3 (Perkin-Elmer). CRISPR screens were 304 
performed with three clones per drug treatment. Mass spectrometry of GFP-FAM35A and 305 
GFP-C20orf196 was performed in two independent experiments. RNA-sequencing was 306 
performed as three replicates for each trial arm, due to sequencing across multiple lanes 307 
(which were merged prior to any further analysis). This was performed for the following 308 
number of independent biological samples: six PDXs in cohort 1, five PDXs in cohort 2, 309 
seven PDXs in cohort 3 and eight PDXs in cohort 4. For the SHLD1 high and low expression 310 
cohorts 12 and 4 independent PDXs were evaluated respectively. All immunofluorescence 311 
assay quantification data represent means ±SEMÕs of 3 independent biological repeats and 312 
n≥30 cells per condition unless otherwise specified. All immunoblots are representative of 313 
two independent experiments with unprocessed scans of immunoblots shown in 314 
Supplementary Fig 8. 315 
 316 
Data availability.  317 
The raw data files for the whole genome CRISPR-Cas9 screen in SUM149 cells is available 318 
on NIH Sequence Read Archive (SRA) via the accession number PRJNA471892. Raw data 319 
files for the PDX RNA sequencing is available on NIH Sequence Read Archive (SRA) via 320 
the accession number PRJNA473981. Raw data files for the mass spectrometry are available 321 
via the ProteomeXchange Consortium on the PRIDE partner repository with the dataset 322 
identifier PXD009830. Source data for figures can be found in Supplementary Table 5. All 323 
other data supporting the findings of this study are available from the corresponding authors 324 
on reasonable request. 325 
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